Valneva Reports Best FY Results in the Company’s History with its First Year of Positive EBITDA in 2016

The Company expects to continue showing a strong financial performance in 2017

Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, reported today its fourth quarter and full year financial results ending December 31, 2016. The annual financial report including the consolidated financial statements 2016 are available on the Company’s website

Thomas Lingelbach, President and CEO and Franck Grimaud, Deputy CEO of Valneva, commented, “2016 has been a successful and transformational year for Valneva as we have mastered the transformation of Valneva into a fully integrated (from Research to Sales), commercial stage biotech company and reported the best results in the Company’s history while still making significant investments in the development of life-saving vaccines. We have also largely exceeded our operational goals across almost every area of our business, leading to strong financial performance. In 2017, we will focus on pursuing this operational performance while at the same time trying to create R&D value through both the advancement and, when appropriate, the partnering of our product candidates.”

Full press release here >>

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)